Regeneron Ticker Symbol Research and Investment Guidance

Regeneron is a well-established biopharmaceutical company with a strong track record of innovation and growth. The company's ticker symbol is REGN.

Regeneron's stock has been listed on the NASDAQ stock exchange since 1996, providing investors with a reliable and stable investment option. With a market capitalization of over $100 billion, REGN is one of the largest biotech companies in the world.

Investors who have been following Regeneron's progress over the years have seen significant returns on their investment. The company's stock has consistently outperformed the broader market, with a compound annual growth rate (CAGR) of over 20%.

For your interest: Ticker Symbol and Stock Exchange for Given Company Neximmune Inc

As we take a closer look at Regeneron's performance, it's worth noting that its trailing total returns as of 10/3/2025 include dividends or other distributions.

Regeneron's performance is benchmarked against the S&P 500 (^GSPC).

Analysts expect the company to report a 15% increase in revenue this quarter, according to the latest consensus estimate.

The average price target for the company's stock is $42.50, indicating a potential upside of 10% from its current price.

Analysts have been revising their estimates downward over the past few weeks, with the median estimate now at $38.75, down from $40.50.

This suggests that analysts are becoming more conservative in their expectations, which could impact the stock's performance.

Additional reading: T Rowe Price Ticker Symbols

Murphy Andrew J, the EVP Research at Regeneron Pharmaceuticals, made some notable insider transactions on August 13 and 14, 2024. He acquired 20,000 shares of common stock on August 13, 2024, at a price of $399.66 per share.

The transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Murphy's total ownership of Regeneron Pharmaceuticals' common stock after these transactions is 68,306 shares.

Suggestion: Common Ticker Symbols

Regeneron Pharmaceuticals, Inc. has a market cap of $63.59 billion, making it a substantial player in the pharmaceutical industry. This valuation is reflected in its enterprise value, which stands at $58.83 billion.

The company's valuation measures indicate a trailing P/E of 15.12 and a forward P/E of 15.46, suggesting a relatively stable and consistent growth trajectory. The PEG ratio of 1.15 indicates that the stock is moderately priced compared to its earnings growth.

Regeneron's price-to-sales ratio is 4.74, and its price-to-book ratio is 2.12, indicating that the stock is priced at a premium compared to its sales and book value.

Here's a summary of Regeneron's valuation measures:

Regeneron's financial performance is expected to continue growing, with projected net sales of $14.63 billion in 2025 and $15.56 billion in 2026. Net income is also expected to increase, reaching $4.25 billion in 2025 and $4.65 billion in 2026.

Regeneron Pharmaceuticals is a biopharmaceutical company focused on treatments for eye diseases, cancer, dermatitis, and rheumatoid arthritis.

Regeneron has collaborated with several major companies, including Amgen, Procter & Gamble, Bayer, Sanofi, and Japan's Sumitomo Chemical.

Suggestion: Regeneron Stock Symbol

The company is a component of the S&P 500 and has more than 15,100 employees worldwide.

Regeneron's marketed products include low-dose Eylea and Eylea HD for wet age-related macular degeneration and other eye diseases, Dupixent in immunology, Praluent for LDL cholesterol lowering, Libtayo in oncology, and Kevzara in rheumatoid arthritis.

Regeneron is developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron's stock price has been adjusted by several analysts, including Guggenheim, Bernstein, and Baird, with price targets ranging from $759 to $1,010.

Here are the recent price target adjustments for Regeneron Pharmaceuticals:

Regeneron's gene therapy study has shown improved hearing in children with congenital deafness, according to recent results from Regeneron's DB-OTO study.

Regeneron's performance is measured against the S&P 500 benchmark, which is a widely followed stock market index.

Additional reading: Sentinelone Stock Symbol

The trailing total returns as of 10/3/2025, include dividends or other distributions, providing a comprehensive view of the company's performance over time.

You can compare Regeneron to similar companies using key performance metrics, allowing you to analyze and identify trends and patterns.

Select up to 4 stocks to compare with Regeneron, giving you a more nuanced understanding of the company's strengths and weaknesses.